Xencor, Inc (XNCR) FY2026 YTD Q2 P&L / Income Statement

Xencor, Inc (XNCR) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Counterparty Name. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Collaborations, milestones, and royalties

55,737,000 US dollars

Total operating expenses

170,667,000 US dollars

Operating loss

negative 114,930,000 US dollars

Total other income (expense)

negative 35,625,000 US dollars

Loss before income tax expense (benefit) and noncontrolling interest

negative 150,555,000 US dollars

Income tax (benefit) expense

90,000 US dollars

Net loss including noncontrolling interest

negative 150,645,000 US dollars

Alexion

38,798,000 US dollars

Incyte

6,839,000 US dollars

Other

100,000 US dollars

Vir Bio

0 US dollars

Zenas BioPharma, Inc.

10,000,000 US dollars

Total operating expenses

170,667,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.